ArticleAlimentary pharmacology & therapeutics2026
Screen-Detected Coeliac Disease in a Nationally Representative Cohort: Health Indicators, Long-Term Outcomes and Mortality.
Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Screen-Detected Coeliac Disease in a Nationally Representative Cohort: Health Indicators, Long-Term Outcomes and Mortality.Alimentary pharmacology & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPopulation-based screening for coeliac disease could reduce underdiagnosis, but benefits and harms remain debated.
aimWe studied health outcomes in screen-detected coeliac disease patients at diagnosis and following a long-term gluten-free diet.
methodsData were collected from Health 2000 and 2011 studies representing the Finnish population. Coeliac disease was screened in 6339 individuals by transglutaminase and endomysial antibodies, with dual seropositivity as the diagnostic criterion, histologically validated in this cohort. Survey-weighted analyses enabled population-level results. The follow-up cohort comprised those participating in both time points. Mortality was assessed between 2000 and 2017.
resultsAt screening, 92 (1.5%) undiagnosed coeliac disease patients and 6216 non-coeliac controls were identified. Patients were less often smokers (11% vs. 22%, p = 0.014), more often had a history of pre-eclampsia (13% vs. 5%, p = 0.037) and anaemia (14% vs. 6%, p = 0.012), and lower ferritin (29 vs. 68 ng/mL, p < 0.001), with an altered lipid profile including lower total cholesterol, LDL-C, and ApoB but higher atherogenic ratios. At 11-year follow-up, mental health, quality of life, and cardiometabolic markers were comparable between treated coeliac disease patients (n = 50) and non-coeliac controls (n = 3226). Mortality did not differ after adjustment for age and sex (HR 0.77, 95% CI 0.45-1.33).
conclusionsNationally screened adults with undiagnosed coeliac disease showed iron deficiency and anaemia. Long-term dietary treatment did not adversely affect quality of life or cardiometabolic health and may prevent complications. Furthermore, mortality was comparable to the general population. The results suggest a favourable benefit-harm balance for population-based screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.